Novo Nordisk’s FREHEMGO Wins EU Approval for Haemophilia A Prophylaxis

Share on Social Media

Novo Nordisk FREHEMGO denecimig EU approval for haemophilia A prophylaxis

Novo Nordisk secures EU approval for FREHEMGO (denecimig), offering monthly, biweekly and weekly prophylactic dosing for haemophilia A.

Written By: Aabha Dey, BPharm

Reviewed By: Pharmacally Editorial Team

Novo Nordisk announced on 13 November 2026 that the European Commission (EC) has granted marketing authorisation for FREHEMGO® (denecimig), a bispecific antibody for routine prophylaxis in patients with haemophilia A. The approval covers adults and children with congenital factor VIII (FVIII) deficiency, with or without FVIII inhibitors. FREHEMGO offers three administration schedules, once monthly, once every two weeks or once weekly, through a single-use pre-filled pen. The authorisation follows a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) in September 2026.

European Commission Grants Marketing Authorisation

FREHEMGO is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children with haemophilia A, with or without inhibitors. Treatment is administered under the supervision of a physician experienced in managing haemophilia and bleeding disorders.

The medicine has also received approval in Saudi Arabia. In the United States, its Biologics License Application (BLA) remains under review by the Food and Drug Administration (FDA). In an October 2026 update, Novo Nordisk reported that ongoing manufacturing-facility remediation activities were responsible for extending the FDA review. The company stated that the FDA had not identified deficiencies in the submitted clinical efficacy or safety data and had not communicated a revised timeline for regulatory action.

FVIIIa-Mimetic Mechanism and Flexible Dosing

FREHEMGO is a fully human modified immunoglobulin G4 (IgG4) bispecific antibody that mimics the cofactor activity of activated factor VIII (FVIIIa). It simultaneously binds activated factor IX (FIXa) and factor X (FX), bringing these clotting factors together and promoting the generation of activated factor X (FXa).

This mechanism supports thrombin generation, an essential process in blood clot formation. Unlike conventional FVIII replacement therapy, denecimig provides FVIIIa-mimetic activity independently of endogenous FVIII, allowing its use in patients with or without FVIII inhibitors.

The treatment is administered subcutaneously through a single-use pre-filled pen. Its three prophylactic schedules are once monthly, once every two weeks and once weekly. Novo Nordisk describes FREHEMGO as the first FVIIIa mimetic to offer all three dosing frequencies through a single-use pre-filled pen, providing additional flexibility in preventive treatment.

FRONTIER Clinical Programme Supports Approval

The marketing authorisation is supported by the FRONTIER clinical development programme, comprising five studies evaluating denecimig in paediatric and adult patients with haemophilia A. FRONTIER2, FRONTIER3 and FRONTIER4 formed the basis of the marketing authorisation application.

The pivotal Phase 3 FRONTIER2 study evaluated once-weekly and once-monthly denecimig in adults and adolescents aged 12 years and older. The study demonstrated reductions in annualised rates of treated bleeding episodes (treated ABR) of 96.4% and 98.7%, respectively, compared with prior on-demand treatment. Against previous FVIII prophylaxis, the corresponding reductions were 54.0% and 42.8%. These findings demonstrate reduced requirements for treatment of bleeding episodes across both comparator groups.

FRONTIER3 evaluated once-weekly and once-monthly dosing in children younger than 12 years. Its findings were consistent with the efficacy observed in adolescents and adults, supporting the treatment’s development across age groups.

FRONTIER4 was an open-label extension study evaluating the once-every-two-weeks regimen and longer-term safety across all three dosing schedules. Together, these three studies supported the regulatory submission.

Switching Evidence and Safety Findings

Emicizumab (Hemlibra), developed by Roche, is an established FVIIIa-mimetic prophylactic treatment for haemophilia A, including patients with FVIII inhibitors. Against this treatment background, FRONTIER5 investigated the safety of directly switching patients from emicizumab to denecimig without a washout period or loading dose.

All 61 participants completed the 26-week study. No thromboembolic events, hypersensitivity reactions or clinical evidence of neutralising anti-denecimig antibodies were observed. Thrombin generation increased into the normal reference range without an exaggerated haemostatic response. Among 59 participants assessed for device experience, 98.3% rated the denecimig pre-filled pen as easy or very easy to use.

Across the FRONTIER programme, denecimig demonstrated consistently low mean annualised bleeding rates, with a substantial proportion of participants experiencing zero treated bleeding episodes. The most common adverse effects include injection-site reactions, increased prothrombin fragment 1+2 and increased fibrin D-dimer. These laboratory changes warrant continued clinical monitoring and interpretation.

Clinical Significance and Regulatory Outlook

Haemophilia affects approximately 1,125,000 people worldwide. Haemophilia A results from a deficiency or dysfunction of clotting factor VIII. Up to 30% of people with severe haemophilia A may develop inhibitors against replacement factor therapy, potentially reducing its effectiveness.

FREHEMGO introduces another prophylactic option through its FVIIIa-mimetic mechanism, particularly relevant to patients with FVIII inhibitors. Its monthly, biweekly and weekly schedules provide additional treatment flexibility. However, FRONTIER5 was a switching and patient-experience study, not a head-to-head efficacy comparison with emicizumab.

Novo Nordisk’s Q3 2026 update indicates that initial European launches are expected around the turn of 2026–2027, followed by broader commercial rollout during 2027. The company is also targeting a US launch in the first half of 2027, subject to FDA approval. National reimbursement and commercial arrangements will influence availability across individual markets.

References

FREHEMGO® (denecimig) approved in the EU for haemophilia A, Novo Nordisk. 13 November 2026.

Update on the denecimig Biologics License Application in the US, Novo Nordisk. 2 October 2026.

ClinicalTrials.gov. FRONTIER2: NCT05053139. https://clinicaltrials.gov/study/NCT05053139

ClinicalTrials.gov. FRONTIER3: NCT05306418. https://clinicaltrials.gov/study/NCT05306418

ClinicalTrials.gov. FRONTIER4: NCT05685238. https://clinicaltrials.gov/study/NCT05685238

ClinicalTrials.gov. FRONTIER5: NCT05878938. https://clinicaltrials.gov/study/NCT05878938

About the Writer

Aabha Dey (LinkedIn) is a Pharmacy Bachelor from Delhi Pharmaceutical Sciences and Research University (DIPSAR), New Delhi. She has a strong interest in pharmacology, clinical research and medical writing, with practical exposure through internships in hospital practice, scientific and journal writing, and medical coding.

Her academic interests include pharmacovigilance, drug development, regulatory affairs and evidence-based healthcare communication. She is particularly interested in scientific research and translating complex pharmaceutical and clinical information into clear, accurate and accessible content.


Share on Social Media
Scroll to Top